NICE TAs

29/04/2020

TA616: Cladribine for treating relapsing–remitting multiple sclerosis

29/04/2020

TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis

29/04/2020

TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

29/04/2020

TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma

29/04/2020

TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy

29/04/2020

TA512: Tivozanib for treating advanced renal cell carcinoma

29/04/2020

TA555: Regorafenib for previously treated advanced hepatocellular carcinoma

29/04/2020

TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer

29/04/2020

TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer

29/04/2020

TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C

29/04/2020

TA588: Nusinersen for treating spinal muscular atrophy

29/04/2020

TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours

29/04/2020

TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy

29/04/2020

TA517: Avelumab for treating metastatic Merkel cell carcinoma

28/04/2020

TA518: Tocilizumab for treating giant cell arteritis

28/04/2020

TA492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

28/04/2020

TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

28/04/2020

TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

28/04/2020

TA513: Obinutuzumab for untreated advanced follicular lymphoma

28/04/2020

TA568: Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)